Breaking News Instant updates and real-time market news.

BMY

Bristol-Myers

$62.47

-0.77 (-1.22%)

, PFE

Pfizer

$36.06

-0.29 (-0.80%)

06:48
12/05/17
12/05
06:48
12/05/17
06:48

Senate tax bill raises odds of Pfizer buying Bristol-Myers, says Citi

The Senate tax bill, which lowers the cost of bringing cash back home from outside the U.S., increases the probability of the "often-discussed" potential acquisition of Bristol-Myers Squibb (BMY) by Pfizer, Citi analyst Andrew Baum tells investors in a research note. The analyst points out that Pfizer has repeatedly underscored the importance of tax reform both from a competitive angle as well as from a merger perspective. Further, the analyst says that while Roche's (RHHBY) IMpower 150 Tecentriq lung cancer data in Geneva will take center stage this week, Bristol-Myers should benefit from two recent positive developments. The FDA's and Centers for Medicare and Medicaid Services' recommendation of Tumor Mutational Burden testing for lung cancer and other tumors will likely materially accelerate adoption and create more favorable reimbursement, Baum writes in a research note partially titled "Stars Converging for BMY." The analyst keeps a Buy rating on Bristol shares with a $72 price target. The stock closed yesterday down 76c to $62.47.

BMY

Bristol-Myers

$62.47

-0.77 (-1.22%)

PFE

Pfizer

$36.06

-0.29 (-0.80%)

RHHBY

Roche

$31.30

-0.61 (-1.91%)

  • 05

    Dec

  • 06

    Dec

  • 07

    Dec

  • 09

    Dec

  • 14

    Dec

  • 23

    Dec

  • 18

    Jan

  • 23

    Feb

  • 05

    Mar

BMY Bristol-Myers
$62.47

-0.77 (-1.22%)

11/03/17
STFL
11/03/17
NO CHANGE
Target $25
STFL
Buy
NewLink Genetics price target lowered to $25 from $29 at Stifel
Stifel analyst Stephen Willey trimmed his price target on NewLink Genetics (NLNK) to $25 from $29 to reflect incremental dilution from its recent equity fundraising and forecast for increased operating expenses given that the company will soon initiate its pivotal Phase 3 melanoma trial. The analyst, who expects NewLink shares to remain sensitive to near-term data points on the IDO inhibitor front from Bristol-Myers (BMY) and the partnership of Incyte (INCY) and Merck (MRK), keeps a Buy rating on NewLink shares.
11/08/17
LEER
11/08/17
NO CHANGE
LEER
Outperform
Leerink sees Five Prime recovering some of yesterday's losses
After hosting an investor call to obtain additional information on the efficacy and safety profile of cabiralizumab in pancreatic cancer, Leerink analyst Michael Schmidt expects shares Five Prime Therapeutics (FPRX) will recover some of the losses from yesterday. The efficacy observed in yesterday's data look "quite promising," while safety looks very similar to what has been seen in Opdivo monotherapy trials historically, Schmidt tells investors in a research note. He notes that Five Prime partner Bristol-Myers (BMY) remains highly engaged in the cabiralizumab program. The analyst maintains an Outperform rating on Five Prime shares. The stock in midday trading is up 15%, or $3.85, to $29.71.
11/13/17
BMOC
11/13/17
NO CHANGE
BMOC
BMO says Pfizer buying Biogen makes more sense than deal for Bristol-Myers
BMO Capital analyst Alex Arfaei noted the "significant market speculation" that Pfizer (PFE) is preparing to execute a large M&A deal. While many sources, including Bloomberg, have speculated that Pfizer could target Bristol-Myers (BMY), Arfaei argues that a deal for Biogen (BIIB) would make more sense. He believes Pfizer has a significant gap in neurology, particularly in Alzheimer's, where it cannot afford to remain on the sidelines as its peers - including Biogen, Merck (MRK), AstraZeneca (AZN), and Eli Lilly (LLY) - all have pivotal trials in that area reading out in 2019-2020. Pfizer could have an opportunity to leverage near-term volatility in Biogen's MS franchise to strike a deal during the next 6-9 months before a potential interim look on aducanumab, which Arfaei views as the strongest of the next wave of Alzheimer's drugs in development, he tells investors.
11/30/17
GABE
11/30/17
NO CHANGE
Target $133
GABE
Buy
Incyte a top biotech pick for 2018 at Gabelli
Gabelli analyst Jing He highlighted Incyte as his top biotech pick for 2018 telling investors shares are undervalued and should benefit from the Epa melanoma data readout in first half 2018. The analyst said shares are trading near a 52-week low despite progress in the pipeline and believes competitors Bristol-Myers (BMY) and NewLink's (NLNK) IDO inhibitors are a few years behind Epa in development. Further, as tax reform gains more clarity, He believes M&A oncology deals could pickup and views Incyte as an attractive takeover target. Jing He rates Incyte a Buy with a $133 price target.
PFE Pfizer
$36.06

-0.29 (-0.80%)

11/01/17
UBSW
11/01/17
NO CHANGE
Target $38
UBSW
Buy
Pfizer risk/reward remains favorable, says UBS
UBS analyst Marc Goodman said he continues to like Pfizer's risk/reward following its Q3 results. The analyst believes the company could unlock some value with potential strategic action on its consumer business and also thinks its pipeline gets minimal credit. Goodman reiterated his Buy rating and $38 price target on Pfizer shares.
11/13/17
PIPR
11/13/17
NO CHANGE
Target $54
PIPR
Overweight
Pfizer still most compelling risk/reward in global pharma, says Piper Jaffray
Piper Jaffray analyst Richard Purkis says Pfizer remains the most compelling long-run risk/reward opportunity in his global pharma coverage universe. He believes the company's key growth assets, or Ibrance, Eliquis, Xtandi, Xeljanz and Bosulif, and pipeline are being underestimated by investors. Pfizer remains one of the analyst's top 2017 picks. Purkis reiterates an Overweight rating on the shares with a $54 price target.
11/14/17
WELS
11/14/17
NO CHANGE
Target $12
WELS
Outperform
Pfizer ADHD drug supply shortage is positive for Neos, says Wells Fargo
Wells Fargo analyst David Maris says Pfizer (PFE) has sent a letter on physicians dated November 8th telling them of a supply shortage for its liquid and chewable methylphenidate ADHD products. Maris says Pfizer's product is a direct competitor of Neos' (NEOS) recently-launched Cotempla XR-ODT, adding Neos will benefit from having its primary competition in the alternative dose market facing a shortage. The analyst says Cotempla XR-ODT, launched in September, is off to a very strong start, keeping his Outperform rating with a $12 price target on Neos.
RHHBY Roche
$31.30

-0.61 (-1.91%)

11/20/17
PIPR
11/20/17
NO CHANGE
Target $71
PIPR
Overweight
Piper a buyer of Bioverativ on Roche study selloff
Piper Jaffray analyst Christopher Raymond says he remains a buyer of Bioverativ (BIVV) after Roche (RHHBY) announced that its Haven 3 Phase III study met its primary endpoint. The analyst is waiting for the full data, expected in May, regarding absolute annualized bleed rates and consistency of effect. He remains confident in his forward estimates for Bioverativ's Eloctate and keeps an Overweight rating on the shares with a $71 price target. Absent full data detailing absolute annualized bleed rates for Roche's Hemlibra, it's difficult to draw too many conclusions on the relative efficacy compared to Eloctate in the non-inhibitor population, Raymond tells investors in a research note.
11/20/17
BTIG
11/20/17
NO CHANGE
Target $242
BTIG
Buy
Shire selloff on Roche news seems overdone, says BTIG
BTIG analyst Timothy Chiang said today's weakness in Shire (SHPG) shares is overdone and creates a potential buying opportunity. While Roche's (RHBBY) emicizumab is likely to gain share at the expense of Shire's Advate, he does not expect a rapid conversion and thinks Shire's pipeline and platform seem overly discounted at current levels. Chiang has a Buy rating and $242 price target on Shire shares.
11/20/17
DBAB
11/20/17
NO CHANGE
Target $53
DBAB
Hold
Deutsche cuts Bioverativ target to $53 after positive Roche data
Deutsche Bank analyst Andrew Peters lowered his price target for Bioverativ (BIVV) to $53 from $65 and remains cautious on the shares following today's positive data from Roche's (RHHBY) Phase 3 study evaluating Hemlibra in noninhibitor hemophilia A patients. While full data is needed to better understand the clinical and competitive profile, the data reported today suggest Hemlibra will likely pressure the longevity and sustainability of Bioverativ's Eloctate franchise, Peters told investors earlier in a research note. The analyst reiterated a Hold rating on Bioverativ shares. The stock closed the trading day down 9.5% to $50.76. Shire (SHPG), another company with a hemophilia franchise, closed today down 4% to $141.37 while Roche rallied 6% to $30.82.
11/22/17
COWN
11/22/17
NO CHANGE
Target $105
COWN
Outperform
Impressive Venclexta abstract positive for AbbVie, says Cowen
Cowen analyst Steven Scala said a late breaking ASH abstract showed impressive data for AbbVie's Venclexta drug used in chronic lymphocytic leukemia. The analyst has modeled $2.6N in sales in 2024 and company guidance suggests sales could reach $6B in 2025. Scala reiterated his Outperform rating and $105 price target on AbbVie shares.

TODAY'S FREE FLY STORIES

RIGL

Rigel Pharmaceuticals

$3.57

-0.15 (-4.03%)

20:21
12/14/17
12/14
20:21
12/14/17
20:21
Initiation
Rigel Pharmaceuticals initiated at Cantor Fitzgerald »

Rigel Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

  • 17

    Apr

PFE

Pfizer

$36.46

-0.18 (-0.49%)

19:32
12/14/17
12/14
19:32
12/14/17
19:32
Hot Stocks
Pfizer announces FDA approval of Xeljanz »

Pfizer announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Jan

HUSKF

Husky Energy

$12.76

0.3377 (2.72%)

18:44
12/14/17
12/14
18:44
12/14/17
18:44
Upgrade
Husky Energy rating change at Credit Suisse »

Husky Energy upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PRAH

PRA Health

$89.13

1.9 (2.18%)

18:41
12/14/17
12/14
18:41
12/14/17
18:41
Initiation
PRA Health initiated at MUFG »

PRA Health initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DIS

Disney

$110.57

2.96 (2.75%)

, FOX

21st Century Fox

$34.22

1.88 (5.81%)

18:31
12/14/17
12/14
18:31
12/14/17
18:31
Periodicals
Experts: Disney-Fox deal may raise antitrust worries, Reuters reports »

Competition experts say…

DIS

Disney

$110.57

2.96 (2.75%)

FOX

21st Century Fox

$34.22

1.88 (5.81%)

FOXA

21st Century Fox

$34.88

2.13 (6.50%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

  • 14

    Dec

  • 14

    Dec

  • 15

    Dec

MESO

Mesoblast

$5.39

-0.07 (-1.28%)

, TIG

TiGenix

$21.67

-2.55 (-10.53%)

18:31
12/14/17
12/14
18:31
12/14/17
18:31
Hot Stocks
Mesoblast grants TiGenix exclusive global license for stem cells treatment »

Mesoblast (MESO) has…

MESO

Mesoblast

$5.39

-0.07 (-1.28%)

TIG

TiGenix

$21.67

-2.55 (-10.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDXG

MiMedx

$12.14

0.15 (1.25%)

18:28
12/14/17
12/14
18:28
12/14/17
18:28
Hot Stocks
MiMedx posts new materials on website exposing misinformation from short sellers »

MiMedx announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,174.26

10.13 (0.87%)

, GOOG

Alphabet

$1,049.15

8.54 (0.82%)

18:23
12/14/17
12/14
18:23
12/14/17
18:23
Periodicals
Amazon to begin selling Apple TV, Chromecast on online store, Reuters reports »

Amazon (AMZN) plans to…

AMZN

Amazon.com

$1,174.26

10.13 (0.87%)

GOOG

Alphabet

$1,049.15

8.54 (0.82%)

GOOGL

Alphabet Class A

$1,057.47

6.08 (0.58%)

AAPL

Apple

$172.22

-0.05 (-0.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Feb

  • 18

    Mar

WM

Waste Management

$84.66

-0.68 (-0.80%)

18:02
12/14/17
12/14
18:02
12/14/17
18:02
Hot Stocks
Waste Management raises quarterly dividend 9.4%, authorizes $1.25B buyback »

Waste Management…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IQV

Iqvia

$101.47

-0.75 (-0.73%)

17:58
12/14/17
12/14
17:58
12/14/17
17:58
Initiation
Iqvia initiated at MUFG »

Iqvia initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SRE

Sempra Energy

$115.78

0.54 (0.47%)

17:40
12/14/17
12/14
17:40
12/14/17
17:40
Hot Stocks
Sempra Energy, Oncor announce settlement with key stakeholders »

Oncor Electric Delivery…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ORCL

Oracle

$50.19

0.14 (0.28%)

17:40
12/14/17
12/14
17:40
12/14/17
17:40
Hot Stocks
Breaking Hot Stocks news story on Oracle »

Oracle says FY18 CapEx…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

ORCL

Oracle

$50.19

0.14 (0.28%)

, AMZN

Amazon.com

$1,174.26

10.13 (0.87%)

17:34
12/14/17
12/14
17:34
12/14/17
17:34
Hot Stocks
Breaking Hot Stocks news story on Oracle, Amazon.com »

Oracle says switching…

ORCL

Oracle

$50.19

0.14 (0.28%)

AMZN

Amazon.com

$1,174.26

10.13 (0.87%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

  • 18

    Mar

EPD

Enterprise Products

$26.07

0.17 (0.66%)

17:33
12/14/17
12/14
17:33
12/14/17
17:33
Hot Stocks
Enterprise Products to implement further oil quality specifications at Cushing »

Enterprise Products…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADBE

Adobe

$175.00

-1.83 (-1.03%)

17:31
12/14/17
12/14
17:31
12/14/17
17:31
Hot Stocks
Adobe 'pleased' with subscription bookings and advertising cloud »

Says photography offering…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

JBL

Jabil Circuit

$27.45

-1.08 (-3.79%)

, COST

Costco

$186.53

-1.75 (-0.93%)

17:30
12/14/17
12/14
17:30
12/14/17
17:30
Hot Stocks
On The Fly: After Hours Movers »

UP AFTER EARNINGS: Jabil…

JBL

Jabil Circuit

$27.45

-1.08 (-3.79%)

COST

Costco

$186.53

-1.75 (-0.93%)

CNC

Centene

$99.02

-2.17 (-2.14%)

DCIX

Diana Containerships

$4.87

-0.37 (-7.06%)

MS

Morgan Stanley

$52.64

-0.54 (-1.02%)

DDR

DDR Corp.

$7.96

-0.11 (-1.36%)

RMBL

RumbleON

$5.30

-0.06 (-1.12%)

SAH

Sonic Automotive

$20.05

-0.95 (-4.52%)

HES

Hess Corp.

$42.67

-1.43 (-3.24%)

FORM

FormFactor

$14.90

-0.05 (-0.33%)

ORCL

Oracle

$50.19

0.14 (0.28%)

VSTM

Verastem

$3.65

-0.15 (-3.95%)

GBT

Global Blood Therapeutics

$39.40

1.05 (2.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

  • 14

    Dec

  • 14

    Dec

  • 15

    Dec

  • 09

    Jan

AEP

American Electric

$76.29

-0.22 (-0.29%)

17:28
12/14/17
12/14
17:28
12/14/17
17:28
Syndicate
Breaking Syndicate news story on American Electric »

American Electric files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SAGE

Sage Therapeutics

$158.03

-6.62 (-4.02%)

17:25
12/14/17
12/14
17:25
12/14/17
17:25
Conference/Events
Sage Therapeutics management to meet with RBC Capital »

Dinner Meeting will be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

  • 14

    Dec

ORCL

Oracle

$50.20

0.14 (0.28%)

17:24
12/14/17
12/14
17:24
12/14/17
17:24
Hot Stocks
Breaking Hot Stocks news story on Oracle »

Oracle CEO Hurd says…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

ADBE

Adobe

$175.00

-1.83 (-1.03%)

17:23
12/14/17
12/14
17:23
12/14/17
17:23
Hot Stocks
Adobe targeting subscription bookings growth of 20% in FY18 »

Says expect quarterly…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

ADBE

Adobe

$175.00

-1.83 (-1.03%)

17:20
12/14/17
12/14
17:20
12/14/17
17:20
Hot Stocks
Adobe says advertising cloud had a 'strong' year »

Says advertising cloud…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

ORCL

Oracle

$50.19

0.14 (0.28%)

17:20
12/14/17
12/14
17:20
12/14/17
17:20
Hot Stocks
Breaking Hot Stocks news story on Oracle »

Oracle says currency…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

ORCL

Oracle

$50.19

0.14 (0.28%)

17:19
12/14/17
12/14
17:19
12/14/17
17:19
Earnings
Oracle sees Q3 adjusted EPS 68c-70c, consensus 72c »

Sees Q3 revenue growth of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

UBA

Urstadt Biddle

$22.71

-0.48 (-2.07%)

, UBP

Urstadt Biddle Properties Inc.

$18.00

-0.01 (-0.06%)

17:17
12/14/17
12/14
17:17
12/14/17
17:17
Hot Stocks
Urstadt Biddle raises quarterly dividend by 0.5c to 27c »

At their regular meeting…

UBA

Urstadt Biddle

$22.71

-0.48 (-2.07%)

UBP

Urstadt Biddle Properties Inc.

$18.00

-0.01 (-0.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ORCL

Oracle

$50.19

0.14 (0.28%)

17:14
12/14/17
12/14
17:14
12/14/17
17:14
Hot Stocks
Oracle says customer adoption of cloud products 'remains very strong' »

Says expects to continue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.